Clinical Study

A Randomized Phase II Study Of Perioperative Mfolfirinox Versus Gemcitabine/Nab-Paclitaxel As Therapy For Resectable Pancreatic Adenocarcinoma.

Posted Date: Jul 6, 2017

  • Investigator: John Morris
  • Co-Investigator: Cathleen Eaglin
  • Specialties: Gastroenterology, Hematology/Oncology, Oncology, Cancer, Surgical Oncology
  • Type of Study: Drug

to compare the effects of two different combinations of FDA-approved chemotherapy drugs. These two combinations are called mFOLFIRINOX (oxaliplatin, irinotecan, and fluorouracil) and gemcitabine plus nab-paclitaxel. These chemotherapy drugs will be given


To Be Eligible For This Study, Patients Must Have Pancreatic Cancer That Can Be Removed By Surgery.


Pancreatic, S1505, Resectable, Cancer, Gastrointestinal

For More Information:

Uc Cancer Institute

  • Search Clinical Studies

  • Research in the News

    UC Study Finds Organs from HCV Donors May Be Safe for Liver Transplant

    A UC researcher says livers from HCV patients who test positive for theantibody made to fight the disease may pose a modest risk of infection and beacceptable for transplant